As of today (2024-04-25), Beyond Air's share price is $1.16.
Beyond Air's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.89. Hence, Beyond Air's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Beyond Air's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 9 years, Beyond Air's highest Price-to-Free-Cash-Flow Ratio was 82.50. The lowest was 31.72. And the median was 49.02.
XAIR's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.73 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.50% per year.
During the past 9 years, Beyond Air's highest 3-Year average Free Cash Flow per Share Growth Rate was 2.50% per year. The lowest was -2.70% per year. And the median was -0.10% per year.
Beyond Air Price-to-Free-Cash-Flow Historical Data
The historical data trend for Beyond Air's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beyond Air's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, Beyond Air's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Beyond Air's Price-to-Free-Cash-Flow falls into.
Beyond Air Price-to-Free-Cash-Flow Calculation
Beyond Air's Price-to-Free-Cash-Flow ratio for today is calculated as
Beyond Air's Share Price of today is $1.16.
Beyond Air's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Beyond Air (NAS:XAIR) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Beyond Air Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Beyond Air's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XAIR has been successfully added to your 